Document is current
Any future updates will be listed below
-
Authors
Puig-Jové, Carlos
Julve, Josep
Castelblanco, Esmeralda
Julián, M Teresa
Amigó, Núria
Andersen, Henrik U
Ahluwalia, Tarunveer S
Rossing, Peter
Mauricio, Dídac
Jensen, Magnus T
Alonso, Núria
-
Funding
Funding for this research was provided by:
Fundació la Marató de TV3 (201602-30-31, 201602-30-31)
Instituto de Salud Carlos III (PI17-00232, PI17-01362)
The Danish Heart Foundation (12-04-R90-A3840-22725, 12-04-R90-A3840-22725, 12-04-R90-A3840-22725)
Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CB15/00071)
- License Information
-
More Information
Article History
Received: 23 January 2022
Accepted: 23 September 2022
First Online: 24 November 2022
Declarations
:
: The original study was approved by the regional ethics committee (H-3-2009-139), and the Danish Data Protection Agency (00934-Geh-2010-003). The investigation has been conducted according to the principles expressed in the Declaration of Helsinki, and all the included participants provided written informed consents.
: Not applicable.
: NAM is stockholders of and serve on the board of director of Biosfer Teslab, a diagnostic laboratory company that performed the lipoprotein and glycoprotein analyses described herein. The remaining authors declared not having anything to disclose regarding conflict of interest with respect to this manuscript.
